Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies  by Kumru, Ozan S. et al.
lable at ScienceDirect
Biologicals 42 (2014) 237e259Contents lists avaiBiologicals
journal homepage: www.elsevier .com/locate/bio logicalsReviewVaccine instability in the cold chain: Mechanisms, analysis and
formulation strategies
Ozan S. Kumru a, Sangeeta B. Joshi a, Dawn E. Smith b, C. Russell Middaugh a, Ted Prusik b,
David B. Volkin a, *
a Macromolecule and Vaccine Stabilization Center, Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA
b Temptime Corporation, Morris Plains, NJ 07950, USAa r t i c l e i n f o
Article history:
Received 19 December 2013
Received in revised form
12 May 2014
Accepted 27 May 2014
Available online 1 July 2014
Keywords:
Cold chain
Vaccine
Stability
Formulation
Lyophilization
Adjuvant* Corresponding author. Tel.: þ1 785 864 6262; fax
E-mail address: volkin@ku.edu (D.B. Volkin).
http://dx.doi.org/10.1016/j.biologicals.2014.05.007
1045-1056/© 2014 The Authors. Published by Elsevier
NC-ND license (http://creativecommons.org/licenses/ba b s t r a c t
Instability of vaccines often emerges as a key challenge during clinical development (lab to clinic) as well
as commercial distribution (factory to patient). To yield stable, efﬁcacious vaccine dosage forms for
human use, successful formulation strategies must address a combination of interrelated topics including
stabilization of antigens, selection of appropriate adjuvants, and development of stability-indicating
analytical methods. This review covers key concepts in understanding the causes and mechanisms of
vaccine instability including (1) the complex and delicate nature of antigen structures (e.g., viruses,
proteins, carbohydrates, protein-carbohydrate conjugates, etc.), (2) use of adjuvants to further enhance
immune responses, (3) development of physicochemical and biological assays to assess vaccine integrity
and potency, and (4) stabilization strategies to protect vaccine antigens and adjuvants (and their in-
teractions) during storage. Despite these challenges, vaccines can usually be sufﬁciently stabilized for use
as medicines through a combination of formulation approaches combined with maintenance of an
efﬁcient cold chain (manufacturing, distribution, storage and administration). Several illustrative case
studies are described regarding mechanisms of vaccine instability along with formulation approaches for
stabilization within the vaccine cold chain. These include live, attenuated (measles, polio) and inactivated
(inﬂuenza, polio) viral vaccines as well as recombinant protein (hepatitis B) vaccines.
© 2014 The Authors. Published by Elsevier Ltd on behalf of The International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/3.0/).1. Introduction
The dramatic success of vaccination in improving human and
animal health is well established. For example, the US Centers for
Disease Control (CDC) ranked vaccination as one of the top ten
public health achievements in the United States in the 20th century
“… resulted in the eradication of smallpox; elimination of polio-
myelitis in the Americas; and control of measles, rubella, tetanus,
diphtheria, Haemophilus inﬂuenzae type b, and other infectious
diseases in the United States and other parts of the world.” [1]. The
past decade (2000e2010) witnessed the development and world-
wide regulatory approval of many important new vaccines offering
protection against bacterial (meningococcal and pneumococcal)
and viral (rotavirus and human papillomavirus) infections. In
addition, new vaccine formulations to protect against inﬂuenza: þ1 785 864 5736.
Ltd on behalf of The International A
y-nc-nd/3.0/).(live, attenuated vaccine administered nasally) and varicella (for
protection against zoster for adults) infections were also success-
fully developed and approved for use. Furthermore, new combi-
nation formulations of more well-established vaccines were
commercialized to reduce the complexity of the vaccination
schedule and to improve compliance including MMRV (measles,
mumps, rubella and varicella), DTaP-HepB-IPV (diphtheria, tetanus
toxoid, acellular pertussis, hepatitis B and inactivated poliovirus),
and DTwP-HepB-Hib (diphtheria, tetanus toxoid, whole cell
pertussis, hepatitis B and Haemophilus inﬂuenzae type B) vaccines.
This availability of numerous new vaccines, combination vaccines,
and improved formulations raises important challenges in terms of
procuring and distributing them worldwide [2-4].
Along with these successes in introducing new vaccines to
improve public health over the past decade, there have been
concomitant major advances in our scientiﬁc understanding of the
basic biological mechanisms of the human innate and adaptive
immune systems as well as themolecular basis bywhich pathogens
cause human disease. Despite these advances, the fulﬁllment of thelliance for Biological Standardization. This is an open access article under the CC BY-
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O.S. Kumru et al. / Biologicals 42 (2014) 237e259238promise of new vaccines is still lacking for many urgently needed,
unmet medical conditions such as protecting against infectious
diseases (e.g., malaria, HIV, RSV) as well as therapeutic treatments
for cancer. In addition, the rapid emergence of new infectious dis-
ease threats to public health (e.g., H1N1 pandemic inﬂuenza) un-
derscores the importance for rapidlymoving from the identiﬁcation
of a new vaccine immunogen in the laboratory to a stable,
commercially available vaccine formulation. Clearly, the need to
develop, produce and distribute new vaccines to address unmet
medical needs remains a high priority for improving public health.
Vaccine formulation development is an important part of the
overall development cycle for producing, testing and approving
new vaccine candidates. Vaccine formulation can be deﬁned as
“converting vaccine antigens to medicines” in which the commer-
cial dosage form not only maintains the potency and stability
during manufacturing and storage, but also is designed to be
conveniently administered to patients. The modern vaccine
formulation development path from the discovery of an immu-
nogen to a usable vaccine includes: (1) physical and chemical
characterization of the antigenic component, (2) development of
stability-indicating assays including potency, (3) evaluation and
optimization of the route of administration and adjuvants (in both
animal models and in clinical trials), and (4) formulation design to
maximize the candidate vaccine's (antigen and adjuvant) stability,
shelf life, and immunogenic potential. A major focus of vaccine
formulation development, in many cases, is the enhancement of
potency through the use of vaccine adjuvants, since many candi-
date immunogens fail to transfer from the laboratory to the patient
due to suboptimal efﬁcacy in humans. One key approach to increase
the success rate for new vaccine candidates is thus to ensure the
appropriate formulation in the presence of conventional and/or
novel adjuvants. Adjuvants not only promote the rate and extent of
an immune response, but can potentially steer the immune
response in the desired direction (e.g., humoral vs. cellular immune
responses). In fact, a review of the ﬁve revolutions in the history of
vaccine development [5] predicts the sixth revolution in vaccinol-
ogy will be the introduction of novel vaccine formulations with
novel delivery systems.The purpose of this review is to raise awareness about the sci-
entiﬁc and technical challenges encountered to successfully
formulate and stabilize different types of vaccines, both in terms of
stability of antigens, adjuvants and their complexes. These efforts
are described in the context of maintenance of vaccine potency
across the vaccine cold chain, during both clinical development and
commercial distribution. Since vaccine stability and potency are
deﬁned by the analytical assays used to measure and monitor their
physical, chemical and biological integrity, the design and devel-
opment of accurate, precise and quantiﬁable analytical methods
plays a key role in these stability assessments.
2. Overview of currently available vaccine formulations
A summary of the composition and stability parameters of some
representative vaccines commercially available worldwide is pro-
vided in Tables 1 and 2 (e.g., FDA approved bacterial and viral
vaccines [6], respectively). Based on published reviews [7e11] and
publically available information online from various manufacturers
and PATH [12], the vaccines listed in Tables 1 and 2 are summarized
from the point of view of key pharmaceutical attributes including
the vaccine type and manufacturer, formulation dosage form, route
of administration, type of adjuvants, and storage considerations
(e.g., shelf-life, heat and freeze sensitivities).
One general trend to note from Tables 1 and 2 is that live,
attenuated vaccines do not contain adjuvants, but are more heat
sensitive to potency loss during storage and distribution. These
vaccines contain weakened, attenuated versions of infectious vi-
ruses and bacteria that must replicate in vivo (and therefore mimic
natural infection). Some live, attenuated vaccines are administered
orally (e.g., OPV and rotavirus) or nasally (inﬂuenza) which mimics
the natural route of infection. Many live vaccines are administered
by parenteral injection (e.g., IM or SC), yet still provide protection
against infections often acquired naturally by other routes (e.g.,
oral-fecal). In addition, live, attenuated vaccines often require only
one or two injections to generate a protective immune response.
From a stability perspective, live, attenuated vaccines are often
freeze-dried (lyophilized) in the presence of a complex mixture of
Table 1
Examples of vaccine types, formulations and stability parameters of FDA-approved bacterial vaccines. Information and data were adapted from Refs. [6,9,12].
Vaccine type Product Manufacturer Formulation
(admin route)
Adjuvant Recommended
storage
Shelf life Freeze
sensitive
Heat
sensitivity
Live, attenuated bacteria
BCG TICE BCG Organon Lyo (ID, PC) None 2e8 C 2 years No 9 days (54 C)
BCG Vaccine Organon Lyo (PC) None 2e8 C N/A No 48 h (23 C)
Typhoid Vivotif Berna Capsule (Oral) None 2e8 C 1 year Yes 12 h (37 C)
Conjugates polysaccharide-carrier
Meningococcal
(Groups ACYW)
Menactra Sanoﬁ Pasteur Liquid (IM) None 2e8 C 1 year Yes N/A
Menveo Novartis Lyo (IM) None 2e8 C 2 years Yes N/A
Pneumococcal (7-valent) Prevnar Pﬁzer Liquid (IM) Aluminum 2e8 C 2 years Yes N/A
Pneumococcal (13-valent) Prevnar-13 Pﬁzer Liquid (IM) Aluminum 2e8 C 2 years Yes 4 days (40 C)
Pneumococcal (23-valent) Pneumovax 23 Merck Liquid (IM, SC) None 2e8 C N/A Yes N/A
H. Inﬂuenzae Hiberix GSK Lyo (IM) None 2e8 C 3 years No 5 weeks (55 C)
ActHIB Sanoﬁ Pasteur Lyo (IM) None 2e8 C 3 years Yes N/A
PedvaxHIB Merck Liquid (IM) Aluminum 2e8 C 3 years Yes N/A
Subunit, puriﬁed bacterial antigens
Tetanus Toxoid a Sanoﬁ Pasteur Liquid (IM, SC) None 2e8 C N/A Yes N/A
Tetanus Toxoid Adsorbed a Sanoﬁ Pasteur Liquid (IM) Aluminum 2e8 C N/A Yes N/A
Anthrax Biothrax Emergent Liquid (IM, SC) Aluminum 2e8 C 4 years Yes N/A
Typhoid Typhim Vi Sanoﬁ Pasteur Liquid (IM) None 2e8 C 3 years Yes N/A
Meningococcal
(Groups ACWY)
Menomune Sanoﬁ Pasteur Lyo (SC) None 2e8 C 3 years Yes 6 weeks (60 C)
Combination vaccines
DTP w/Hepatitis B Pediarix GSK Liquid (IM) Aluminum 2e8 C N/A Yes N/A
DTP Infanrix GSK Liquid (IM) Aluminum 2e8 C 3 years Yes N/A
Tripedia Sanoﬁ Pasteur Liquid (IM) Aluminum 2e8 C N/A Yes N/A
Daptacel Sanoﬁ Pasteur Liquid (IM) Aluminum 2e8 C N/A Yes N/A
DTP w/inactivated Polio Kinrix GSK Liquid (IM) Aluminum 2e8 C N/A Yes N/A
H. Inﬂuenzae, HepB Comvax Merck Liquid (IM) Aluminum 2e8 C N/A Yes N/A
Diphtheria and Tetanus. a Sanoﬁ Pasteur Liquid (IM) Aluminum 2e8 C N/A Yes N/A
DecaVac Sanoﬁ Pasteur Liquid (IM) Aluminum 2e8 C N/A Yes N/A
TeniVac Sanoﬁ Pasteur Liquid (IM) Aluminum 2e8 C N/A Yes N/A
Diphtheria,
Tetanus
Mass Biologics Liquid (IM) Aluminum 2e8 C N/A Yes N/A
Tetanus Toxoid,
Diphtheria, & Acellular
pertussis
Adacel Sanoﬁ Pasteur Liquid (IM) Aluminum 2e8 C 3 years Yes N/A
Boostrix GSK Liquid (IM) Aluminum 2e8 C 3 years Yes N/A
Diphtheria and Tetanus,
Acellular Pertussis,
Inactivated Polio,
Haemophilus b
Pentacel Sanoﬁ Pasteur Liquid (IM) Aluminum 2e8 C N/A Yes N/A
Meningococcal, Hib
(Groups CY-Hib)
Menhibrix GSK Lyo (IM) None 2e8 C N/A No N/A
N/Aenot available.
a No trade name identiﬁed.
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term storage. Freeze-dried vaccines necessitate reconstitution
immediately prior to administration and thus require an appro-
priate diluent. Live attenuated vaccines tend to be heat sensitive
during long-term storage in the solid state and during short-term
storage upon reconstitution prior to administration. These vac-
cines thus tend to require careful maintenance of the vaccine cold
chain. One challenging example is the varicella-containing vac-
cines, which often require frozen storage to ensure long stability,
even in the lyophilized state, and can lose potency relatively rapidly
when stored refrigerated.
A second general trend to highlight from Tables 1 and 2 is that
non-replicating vaccines often contain adjuvants to enhance im-
mune responses. These vaccines include inactivated viruses and
bacteria, puriﬁed subunit protein and carbohydrate antigens, and
recombinant subunit protein antigens. Since these vaccines cannot
replicate in vivo, adjuvants are usually required to provide sufﬁ-
cient levels of protective immunity. In addition, inactivated and
subunit vaccines usually require a series of three or moreinjections, often over a 6 month period. The need for multiple
injections over such a long period presents multiple challenges
not only to ensure patient compliance, but also in terms of
maintaining vaccine supply and stability. From a long-term storage
viewpoint, inactivated and subunit vaccines are generally more
stable and are typically developed as liquid formulations. These
vaccines, however, can be freeze sensitive to potency loss during
storage and distribution.
3. Molecular properties of vaccine antigens
The goal of most vaccines is to simulate natural infections by
pathogenic organisms. Thus, the use of both live, attenuated as well
as killed bacteria and viruses provide natural agents for this pur-
pose and have historically constituted the majority of the most
successful vaccines. For example, attenuated viral vaccines are
usually created by extended passage of the wild-type virus in cell
culture to weaken the virus, including at different temperatures, in
different cell lines, and/or in the presence of a mutagen. The
Table 2
Examples of vaccine types, formulations and stability parameters of FDA-approved viral vaccines. Information and data were adapted from Refs. [6,9,12].
Vaccine type Product Manufacturer Formulation
(admin route)
Adjuvant Recommended
storage
Shelf life Freeze
sensitive
Heat
sensitivity
Live, attenuated virus
Varicellaa Varivax Merck Lyo (SC) None Frozen 2 years No 6 h (27 C)
Zostera Zostavax Merck Lyo (SC) None Frozen 18 months No N/A
Rotavirus Rotarix GSK Lyo (Oral) None 2e8 C 3 years No 7 days (20 C)
RotaTeq Merck Liquid (Oral) None 2e8 C 2 years N/A N/A
Inﬂuenzad Flumist MedImmune Liquid (Nasal) None 2e8 C 18 weeks Yes N/A
Adenovirus (Type 4 & 7) b Barr Labs Tablet (Oral) None 2e8 C N/A Yes N/A
Smallpox ACAM2000 Sanoﬁ Pasteur Lyo (PC) None Frozen 18 months No N/A
Yellow Fever YF-Vax Sanoﬁ Pasteur Lyo (SC) None 2e8 C 3 years Yes N/A
Inactivated virus
Hepatitis A Vaqta Merck Liquid (IM) Aluminum 2e8 C 3 years Yes 3 months (28 C)
Havrix GSK Liquid (IM) Aluminum 2e8 C 3 years Yes 1-3 weeks (37 C)
Inﬂuenza Fluarixd GSK Liquid (IM) None 2e8 C 1 year Yes 12 weeks (20 C)
Flulavald ID Biomed Liquid (IM) None 2e8 C 1 year Yes N/A
Agriﬂu Novartis Liquid (IM) None 2e8 C 1 year Yes N/A
Fluvirin Novartis Liquid (IM) None 2e8 C 1 year Yes N/A
Fluzoned,f Sanoﬁ Pasteur Liquid (IM) None 2e8 C N/A Yes N/A
Flucelvax Novartis Liquid (IM) None 2e8 C C N/A Yes N/A
Aﬂuria CSL Limited Liquid (IM) None 2e8 C 1 year Yes N/A
H5N1 Sanoﬁ Pasteur Liquid (IM) None 2e8 C N/A Yes N/A
H5N1 ID Biomed Liquid (IM) AS03e 2e8 C N/A Yes N/A
b2009 (H1N1) CSL Limited Liquid (IM) None 2e8 C N/A Yes N/A
b2009 (H1N1) MedImmune Liquid (Nasal) None 2e8 C N/A Yes N/A
b2009 (H1N1) ID Biomed Liquid (IM) None 2e8 C N/A Yes N/A
b2009 (H1N1) Novartis Liquid (IM) None 2e8 C N/A Yes N/A
b2009 (H1N1) Sanoﬁ Pasteur Liquid (IM) None 2e8 C N/A Yes N/A
Rabies RabAvert Novartis Lyo (IM) None 2e8 C 3 years No 3 months (37 C)
Imovax Sanoﬁ Pasteur Lyo (IM) None 2e8 C N/A Yes N/A
Polio IPOL Sanoﬁ Pasteur Liquid (IM, SC) None 2e8 C 2 years Yes N/A
Japanese Encephalitis Ixiaro Intercell Liquid (IM) Aluminum 2e8 C 1 year Yes N/A
JE-Vax Osaka Lyo (SC) None 2e8 C N/A Yes 1 month (27 C)
Recombinant vaccines
Hepatitis B Engerix B GSK Liquid (IM) Aluminum 2e8 C 3 years Yes 72 h (25 C)
Recombivax HB Merck Liquid (IM) Aluminum 2e8 C 3 years Yes N/A
Human Papilloma Virus Gardasil Merck Liquid (IM) Aluminum 2e8 C 3 years Yes 3 months (45 C)
Cervarix GSK Liquid (IM) AS04c 2e8 C 4 years Yes 7 days (37 C)
Inﬂuenza FluBlock Protein Sciences Liquid (IM) None 2e8 C 16 weeks Yes N/A
Combination vaccines
MMR M-M-R II Merck Lyo (SC) None Frozen 2 years No 7 days (37 C)
DTP w/Hepatitis B Pediarix GSK Liquid (IM) Aluminum 2e8 C N/A Yes N/A
DPT w/inactivated Polio Kinrix GSK Liquid (IM) Aluminum 2e8 C N/A Yes N/A
Hepatitis A & B Twinrix GSK Liquid (IM) Aluminum 2e8 C 3 years Yes 1 week (37 C)
MMR w/Varicella ProQuad Merck Lyo (SC) None Frozen 2 years No N/A
N/Aenot available.
a Refrigerated formulation available.
b No trade name identiﬁed.
c Aluminum hydroxide and lipid A.
d Quadrivalent formulations available.
e Squalene, DL-a-tocopherol, and polysorbate 80.
f High dose intradermal formulation available.
O.S. Kumru et al. / Biologicals 42 (2014) 237e259240resultant attenuated viruses retain the ability to replicate and are
immunologically highly similar to the wild type agent, but display
dramatically reduced pathogenicity. These live attenuated vaccines
usually consist of a mixture of the infectious viral agent in the
presence of an excess of inactive viral particles complicating their
analysis. Both enveloped and non-enveloped viruses have been
developed as vaccines, and the former (containing a lipid bilayer)
are typically less stable and rapidly lose potency. In fact, live
attenuated, enveloped viruses (e.g., measles, mumps, varicella)
often require both complex formulations of numerous excipients
and subsequent lyophilization to obtain adequate storage stability
[7]. Some non-enveloped viruses such as polio and rotavirus, which
possess higher intrinsic stability, have been formulated as liquidpreparations for oral administration. Live attenuated vaccines may
retain a low level of pathogenicity in a very small number of re-
cipients. This disadvantage combined with their marginal stability
has resulted in a search for alternatives.
Inactivated viruses and bacteria offer the advantage of little, if
any, biological pathogenicity and often-improved stability. They are
usually inactivated by chemical crosslinking with reagents such as
formaldehyde. Although these “killed” antigens may be less
immunogenic than their live counterparts, the addition of adju-
vants such as aluminum salts can boost their effectiveness. Inacti-
vated preparations of viruses and bacteria remain highly
heterogeneous vaccine antigens, however, and their replacement
by better deﬁned antigens remains a desirable goal. Successful
O.S. Kumru et al. / Biologicals 42 (2014) 237e259 241examples of inactivated viral vaccines include inﬂuenza (ﬂu),
hepatitis A, and polio (IPV).
With the advent of recombinant DNA technology, individual
components of these large complex bacteria or viruses have been
employed. In the case of viral vaccines, surface proteins have
been cloned and isolated, and in some cases, these viral proteins
spontaneously form virus-like particles (VLPs). Although viral
surface proteins that form VLPs have proven to be highly suc-
cessful as vaccines (for example, hepatitis B and human papil-
lomavirus), monomeric recombinant viral protein antigens are
usually only weakly immunogenic and have yet to prove them-
selves useful vaccine candidates even when supplemented with
potent adjuvants. The greater efﬁcacy of VLPs appears to arise
from their multi-epitopic nature. Most viruses and to some
extent bacteria have coats of one or a few proteins present in a
geometrically regular manner on their surface. The innate im-
mune system possesses receptors that have evolved to recognize
the patterns of such molecules [13,14]. Thus, VLPs better simulate
the natural pathogen accounting for their increased effectiveness
as immunogens compared to their monomeric counterparts.
These complexes are often very stable, adding to their utility as
immunogens. It is also possible to produce related molecular
complexes in the form of membrane bound vesicles, sometimes
referred to as “virosomes”. They can be genetically engineered in
a variety of different cell types. This approach has proven to be a
clinically effective approach to prepare inﬂuenza vaccines (e.g., a
Russian ﬂu vaccine; [15]). Because virosomes contain a lipid
bilayer, they are not only less stable than non-enveloped VLPs,
they are also relatively heterogeneous compared to conventional
VLPs [16,17].
Other vaccine antigens include polysaccharides, both free and
conjugated to various proteinaceous carriers. Both polysaccharides
and their conjugates have been used in highly successful vaccines
[18,19]. Free polysaccharide based vaccines, such as those used in
the prevention of adult pneumonia, are obtained in a relatively
puriﬁed form from a wide variety of different bacterial subtypes
(e.g., 23 different types) to produce vaccines with wide coverage.
Such polysaccharide antigens are however insufﬁciently immuno-
genic in children and have therefore been conjugated to several
different protein carriers (e.g., nontoxic mutants of diphtheria
toxin, CRM197, and a meningococcal outer membrane protein com-
plex, OMPC, from Neisseria meningitides, etc.) to improve T-cell
immunity [20]. Despite the complexity of such vaccines due to the
large carbohydrate entity, the nature of the protein carrier, and the
conjugative process, polysaccharide conjugate vaccines can be
successfully manufactured at large scale and have become an
effective vaccine strategy. For example, vaccines against Haemo-
philus inﬂuenzae type b [18] and Streptococcus pneumonia [19] are
now widely available.Fig. 1. Structure and size range of various viral and bacterial vaccine antigens. Adapted and
for Microbiology, Nature Publishing Group, and Cambridge University Press. Antibody struct
micrograph of the Salmonella typhi cell was kindly provided by the CDC (in public domain)As shown schematically in Fig. 1, vaccine antigens range in size
from the relatively small (such as recombinant proteins, ~5e10 nm)
to the very large (e.g. attenuated bacteria, ~2000 nm). Most viruses
and VLP antigens are in the size range of tens to hundreds of
nanometers. This diversity of size and consequently internal
structure present a signiﬁcant challenge in terms of stabilization
and formulation of vaccines. Although there is no direct relation-
ship between size and stability, a few general comments can be
offered. Large entities such as bacterial cells and enveloped viruses
tend to display limited stability due to the number of their com-
ponents and the complexity of their interactions. For example,
enveloped viruses contain lipid bilayers, which usually display only
moderate to low stability due to their osmotic sensitivity as well as
the complex composition of their lipid, carbohydrate and protein
components. The role of these individual macromolecular agents in
providing overall viral stability is usually not known, adding to the
difﬁculty in their analysis and understanding their role in designing
stabilized formulations. Nonetheless, maintaining the structural
integrity of lipid bilayer of a virus has been identiﬁed as the rate
limiting structure in stability loss [7]. Small, non-enveloped viruses
and VLPs are often much more stable due to the regular nature of
the interaction between their protein subunits. VLPs usually consist
of only one or a few viral surface proteins. The inherent stability of
viral proteins, both individually and as part of the viral capsid, are
highly variable, ranging from low to high, and requires extensive
empirical characterization. While the RNA/DNA and carbohydrate
components of viruses and bacteria are usually considered more
stable, they are still subject to both physical and chemical degra-
dation processes. Polysaccharide vaccine antigens are prone to
hydrolytic degradation reactions over time [21,22]. Nucleic acids
contain helical secondary structure while RNA may contain regions
of tertiary structure, which can be particularly susceptible to
unfolding. As one would expect, the nucleic acid bases are subject
to a wide variety of chemical changes including oxidation. The
subject of pharmaceutical stability of nucleic acids is delineated in
detail elsewhere [23,24]. As discussed in more detail in the
following section, it is always necessary, whatever the nature of an
antigen, to conduct extensive stability studies, both under accel-
erated conditions (e.g., pH, temperature, ionic strength, mechani-
cal, and freeze/thaw) as part of vaccine formulation development,
as well as under actual storage conditions to establish shelf-life and
expiry dating at the recommended storage temperature.
4. Vaccine adjuvants
Vaccine adjuvants are typically added to inactivated and subunit
vaccines to boost protective immune responses. Although the
precise immunological mechanism(s) of vaccine induced protective
immunity remains an active area of research, vaccines have beenreproduced from Refs. [173,194e198], with permission from Elsevier, American Society
ure was obtained from the RCSB Protein Data Bank (accession #1IGT), and the electron
.
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neutralizing antibodies (as measured by antibody types, amounts,
and afﬁnity as well as by pathogen neutralization). In some cases,
other correlates such as ADDC activity, complement activation and
the presence of certain T-cells types linked with cellular immunity
have been established [25]. Compared to live, attenuated vaccines,
subunit vaccines are typically better tolerated and lack the risk of
reversion and subsequent infection, yet they typically are not suf-
ﬁciently immunogenic in terms of generating the breadth and
depth immune responses needed for complete protection.
Only a small number of vaccine adjuvants have been approved
for human use. Many novel candidate adjuvants, however, are in
clinical development with the goal of eliciting speciﬁc immune
responses, especially for urgent unmet medical needs such as
therapeutic cancer vaccines as well as prophylactic preventative
treatment for HIV, malaria and tuberculosis [26]. For example,
activation of different subsets of helper Tcells has been shown to be
required for the most effective host immune response against
different pathogens [25]. New adjuvants have also been explored
for use with commercially available vaccines for dose sparing ap-
plications as well as for expanding use into poorly responding
populations such as elderly and immunocompromised individuals.
Aluminum salts are by far the most commonly used adjuvants
in human vaccines (see Tables 1 and 2). This is primarily due to
their excellent safety record over ~70 years of use in a wide variety
of childhood vaccines. Despite their long history, the biological
mechanism of action of aluminum salt adjuvants has only recently
become better elucidated. Aluminum adjuvants have been shown
to facilitate and increase antigen uptake by immune cells as well
as to act as an immune stimulant to attract immune cells to the
site of injection [27]. Further, aluminum adjuvants appear to
activate antibody responses in a manner independent of the toll-
like receptors of the innate immune system [25]. From a formu-
lation and stability perspective, aluminum salts can vary in terms
of their chemical compositions, which in turn can affect other
physical properties such as particle size, morphology, surface
charge, and vaccine antigen binding capacity [28,29]. The physical
properties of three different aluminum salt vaccine adjuvants are
summarized in Table 3 [28]. These differences in physical prop-
erties greatly inﬂuence the interaction of the vaccine antigens
with different aluminum adjuvants. For example, at pH 7,
aluminum phosphate and aluminum hydroxide have opposite
surface charges (negative and positive, respectively) and therefore
bind different amounts of protein depending on the surface charge
of the antigen (Table 3).
In the past decade, several new adjuvants have been approved
for use by regulators in various countries. These include oil-in-
water emulsions in ﬂu vaccines (e.g., MF59 and AS03 produced
by Novartis and GSK, respectively) as well as the addition of
monophosphoryl lipid A (MPL) in combination with aluminum
adjuvants to recombinant protein (virus-like-particle) vaccines
such as HPV and HBV [26,30]. The MF59 adjuvant contains
squalene-based emulsion particles suspended in citrate buffer and
are stabilized with detergents (Span 85 and polysorbate 80).
Although these particles do not appear to bind or associate withTable 3
Selected physical and chemical properties of aluminum-containing adjuvants. Table was
Commercial designation Chemical formula Structure Morpholog
Aluminum hydroxide AlOOH Crystalline boehmite Thin Fibril
Aluminum phosphate Al(OH)x(PO4)y Amorphous Plate-like
Alum-precipitated Al(OH)x(PO4)y(SO4)z Amorphous Plate-like
a BSA.
b Lysozyme.vaccine antigens, MF59 leads to enhanced antigen update and
recruitment of various immune cells to the injection site [31]. MPL
is a lipopolysaccharide derivative similar to those found on the
surface of gram negative bacteria, and thus activates the innate
immune system as a ligand for the TLR4 receptor [25]. There are
many additional adjuvant candidates in preclinical and clinical
development [32e34], many of which are toll receptor agonists
targeting different pattern recognition receptors found on immune
cells (e.g., dendritic cells in the immature state) of the innate im-
mune system [34]. These in turn activate and regulate immune cells
(e.g., mature dendritic cells, T and B cells) of the adaptive immune
system. This leads to either an antibody and/or cell based immune
response [25]. From a vaccine formulation perspective, adjuvants
can fail not only due to insufﬁcient levels of the correct immune
response or excess reactogenicity, but also by causing destabiliza-
tion of vaccine antigens during storage [26].
It should also be noted that the immune response generated
from different adjuvants can be affected by the route of adminis-
tration. Vaccine formulations can be administered by parenteral
injection to different tissues (intradermal, subcutaneous, intra-
muscularly) or without injection by either oral delivery or nasal
administration [35]. For example, commercial Hepatitis B (HBV)
vaccines are administered by IM injection. This vaccine contains a
recombinant, puriﬁed VLP viral surface protein in a lipid bilayer as
well as an aluminum adjuvant. The development of needle free
administration of HBV, however, remains an active area of research
with the goal of the elimination of needles, improved compliance
and enhanced immune responses. Further examples include the
use of novel vectors, adjuvants or delivery devices [36]. There has
also been ongoing interest in developing intradermal delivery,
which has the potential for dose sparing. Clinical trials have been
facilitated by new and improved devices for injection including
specialized needle and syringes, microneedles and liquid injectors
[37].
5. Vaccine formulation development
Subsequent to the selection of the vaccine antigen and adjuvant,
a pharmaceutical formulation must be developed to ensure a pre-
dictable level of potency during long-term storage and distribution,
as well as to provide convenient and appropriate administration to
a target patient group. Not only does the nature of the interaction
(or non-interaction) of the vaccine antigen with adjuvant need to
be characterized, but the optimal state of this interaction must be
preserved during storage and administration to ensure acceptable
immune responses from the beginning to the end of the shelf-life of
the vaccine.
Live, attenuated viral and bacterial vaccines are sensitive to
environmental stress, especially elevated temperatures, and often
require lyophilization to preserve potency during long-term stor-
age and distribution (see Tables 1 and 2). This is not surprising since
intact viruses and bacteria replicate in vivo and must maintain their
ability to infect cells. This requires intact native structures of pro-
teins, DNA/RNA and lipid bilayers. Freeze-dried (lyophilized) vi-
ruses and bacterial vaccines usually contain amixture of cell cultureadapted from Ref. [28] with permission from Springer.
y pI Protein adsorptive capacity, mg/ml Al, pH 7.4 Solubility in citrate
s 11 1.8e2.6a ~0%
5e7 0.7e1.5b 55%
6e7 1.0e1.3b Not determined
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as excipients that permit successful freeze-drying, stabilization of
microorganisms, and acceptable pharmaceutical properties such as
intact physical appearance (no cake collapse) and rapid
reconstitution.
The lyophilization process involves controlled removal of water
under decreased pressure and speciﬁc temperature conditions
through various steps that include sample freezing, primary drying
(sublimation of bulk water), and secondary drying (desorption of
bound water) [38e40]. A variety of stresses are encountered during
the freeze-drying steps (low temperature, phase separations, pH
and ionic strength changes, and ice crystal formation among
others) which necessitates the presence of lyo- and cryoprotectants
as well as other stabilizing additives in the formulation to prevent
or minimize the damaging effects of these stresses on the vaccine's
stability and potency. A simultaneous optimization of the formu-
lation composition and freeze-drying process is often required to
obtain a stable vaccine product. It is also imperative that potency of
the vaccine be assessed at each stage of freeze-drying process (e.g.,
freezing, primary drying, secondary drying). Successfully lyophi-
lized vaccines should have a uniform cake appearance with no
obvious signs of cake collapse and be able to be reconstituted easily,
completely and quickly whenmixed with a diluent. The factors that
can impact the stability and potency of lyophilized vaccines include
sample residual moisture content, sealing atmosphere composition
and storage conditions such as temperature, humidity and light
[39].
The lyophilized vaccine product is subsequently stored for
months to years, under appropriate conditions, and then recon-
stituted immediately before administration to the patient. Recon-
stitution refers to the process of mixing of the freeze-dried vaccine
powder with the diluent (liquid). Diluents for lyophilized vaccines
vary in their composition and volume and are speciﬁcally designed
to meet the pH, volume and chemical requirements of each vaccine
[41]. While some diluents consist of sterile water, others may
contain ingredients that not only help dissolve the freeze-dried
powder but also stabilize (e.g., saline) and/or maintain the steril-
ity of the reconstituted vaccine (e.g., preservatives). The volume of
the diluent provided with a vaccine product is dependent on
whether a single or multi-dose vial of vaccine will be reconstituted.
The stability of reconstituted lyophilized vaccines is limited, both in
terms of potency and ensuring sterility, and usually is used within
hours or must be discarded. Therefore, once reconstituted, these
vaccines should be stored under appropriate conditions (lower
temperatures, protect from light, etc.) to better maintain the min-
imum required potency and sterility.
Although lyophilization technology has resulted in the devel-
opment of many successful live, attenuated viral and bacterial
vaccines, most of these vaccines still require storage at 2e8 C or
below which necessitates a cold chain for acceptable long term
stability. A better understanding of themolecular basis or the origin
of the instabilities of viruses and bacteria should result in the more
rational design of stable vaccine formulations. In addition, alter-
native methods of processing such as spray drying may also lead to
improved vaccine stability [40].
Non-replicating vaccines such as inactivated viruses/bacteria,
puriﬁed subunit protein and carbohydrate antigens, VLPs, etc., are
often more stable and can be formulated as liquid solutions stored
in glass vials and/or preﬁlled syringes (it should be noted thatWHO
uses syringes only if they are auto-disabled). As discussed above,
these vaccines also typically contain adjuvants to boost immune
responses. Liquid vaccines are generally formulated to contain
various compounds (excipients) that stabilize the antigen and
prevent drastic conformational alterations over time that could
lead to diminished potency. Optimization of buffer type, pH, ionicstrength, and other stabilizing excipients is a key step in developing
a successfully stabilized vaccine. Utilizing “generally regarded as
safe” or GRAS excipients is the most straightforward place to start
in identifying stabilizing excipients for vaccine formulations, since
they have been classiﬁed as safe for food consumption [42]. It
should be noted, however, that worldwide regulatory agencies have
not necessarily approved GRAS compounds for use in injectable
pharmaceuticals and vaccines. In this regard, the FDA provides a
web-based database for excipients used in pharmaceuticals and
vaccines (FDA inactive ingredient guide), including amounts and
routes of administration [42,43].
Multi-dose vial formulations contain small amounts of pre-
servatives that are bactericidal and bacteriostatic agents. Pre-
servatives ensure the multi-dose vaccine can be used several
times and over an extended period of time. One challenge with
multi-dose presentations containing anti-microbial agents is the
destabilizing effects many of these agents have on the potency
and physical stability of some biological drugs and vaccines [44].
In this regard, single-dose preﬁlled syringes and vials, which are
not formulated with preservatives, may be the only practical
option.
Most liquid vaccine formulations of inactivated or subunit vac-
cines contain aluminum adjuvants to enhance immune responses.
Although the generic term “alum” is frequently used in the vaccine
literature, aluminum salt adjuvants are prepared by different pro-
cesses and starting materials and therefore can actually vary
dramatically in terms of their chemical composition, morphology
and surface charge (Table 3). The adsorption mechanism of antigen
to aluminum salts that is most frequently optimized in terms of
vaccine formulation design is electrostatic interactions, although
other physical mechanisms of interaction have been frequently
reported (e.g., hydrophobic forces, ligand exchange, etc.) [45,46].
Brieﬂy, adsorption is typically optimized by determining the iso-
electric point (pI) of the antigen followed by selecting the oppo-
sitely charged aluminum salt, or selection of appropriate pH and
buffering agents, resulting in an aluminum adjuvant with the
opposite surface charge. Most commonly this involves addition of
phosphate to aluminum hydroxide to lower its surface positive
charge. Characterization and optimization of adsorption is con-
ducted by obtaining an adsorption isotherm, which is produced by
mixing increasing concentrations of aluminum salt with antigen or
vice versa, centrifugation of the adsorbed antigen-adjuvant com-
plex, followed by measurement of the amount of antigen that re-
mains in solution, usually by UV-absorbance spectroscopy [47]. The
need for careful optimization of the interaction of vaccine antigen
and aluminum adjuvant is not always well recognized and it has
been proposed that this become a key part of successfully designing
vaccine formulations [48e50].
Intuitively, one might assume that the amount of antigen bound
to an aluminum salt would be proportional to the robustness of the
immune response, with perhaps a linear relationship. In practice,
however, the amount of antigen adsorbed to the aluminum salt
does not always correlate with a robust immune response since the
soluble antigen itself, and the formulation components (e.g.,
phosphate) can play a role in immunological outcomes. Another
important parameter, termed the adsorptive coefﬁcient, is a mea-
sure of the strength of binding between the antigen and the
aluminum adjuvant and can also play a role in immunogenicity
[51]. It has been proposed that adsorption that is too strong could
interfere with antigen processing and presentation by antigen
presenting cells. Impaired antigen presentation would lead to poor
B-cell activation, which would inevitably result in poor immuno-
globulin secretion by plasma cells [51]. In some cases, weakened
binding of antigen to aluminum produces an improved immune
response [51,52].
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cause structural perturbations or changes in antigen conforma-
tional stability. For example, the thermal stability of several model
antigens was decreased when adsorbed to aluminum adjuvant
when compared to the soluble antigen alone [53]. These effects
may be mitigated by addition of stabilizing excipients to the
formulation [53]. Addition of excipients that increase the thermal
stability (e.g., pH of buffer and phosphate concentration in the case
of the Hepatitis B vaccine) can be used to generate more stable
formulations [54,55]. Recent experimental work has also shown
successful lyophilization of vaccines that contain aluminum adju-
vants, with limited aggregation upon reconstitution [56,57]. Since
aluminum adsorbed vaccines are sensitive to freeze-thaw damage,
formulation strategies that include the addition of compounds that
depress the freezing point (e.g., polyols) are an attractive solution to
protect aluminum adjuvanted vaccines during exposure to freezing
temperatures [10]. The formulation and stability of aluminum
adjuvanted vaccines, such as HBV vaccines, are discussed in more
detail in the case study section below.
6. Vaccine analysis and stability proﬁles
The key step to successfully monitor vaccine stability is identi-
ﬁcation of analytical test(s) with clinical relevance. This assay is
referred to as the “potency test” and is deﬁned as the “speciﬁc
ability or capacity of the product, as indicated by appropriate lab-
oratory tests or by adequately controlled clinical data obtained
through administration of the product in the manner intended, to
effect a given result” [58]. The potency assay not only permits a
linkage between test results and the established safety and efﬁcacy
of the vaccine as determined in clinical trials, but also provides a
mechanism to monitor subsequent commercial lots and evaluate
their quality and stability from the perspective of pivotal clinical
trials [58,59]. Due to their macromolecular complexity, it has not
been possible to date to identify a physicochemical assay that can
be directly related to vaccine's potency. Thus, biological assays (i.e.,
in vivo animal immunogenicity tests or in vitro cell-based orFig. 2. Analysis of the stability proﬁle of a hypothetical live virus vaccine. (A) Determination
[199], (B) stability proﬁle showing lower 95% conﬁdence interval (dashed line) remains wi
month shelf-life [60], and (C) Handling and storage conditions during manufacturing, transp
from Elsevier.antibody binding-based assays) are the cornerstone of vaccine
potency and stability testing. These biological potency assays
typically have low precision (i.e., high variability) leading to
numerous practical challenges in terms of establishing a vaccine's
shelf-life and appropriate storage and handling conditions.
The overall goals of a vaccine stability program during clinical
development are to (1) ensure that a vaccine remains clinically
effective as deﬁned by a lower potency limit, (2) assure a vaccine is
clinically safe at the upper potency limit, and (3) conﬁrm that a
vaccine remains within the boundaries of the upper and lower
potency limits throughout its shelf-life [58]. These goals are shown
schematically in Fig. 2A where the potency value of a hypothetical
vaccine at the time of manufacturing (i.e., the release potency) is
determined from a combination of assay variability, stability loss
rate (and its inherent variability), and the required minimum po-
tency at the expiry date [60,61]. Due to the variability of biological
potency assays, multiple vials of the vaccine are typically tested at
any one-time point and a mean potency is reported. The associated
errors of these measurements are typically determined during
stability testing by determining the lower 95% conﬁdence interval
of the slope of the potency vs. time plots. For example, as shown in
Fig. 2B, a linear regression line is ﬁtted to the mean potency data
(solid line) and the corresponding lower 95% conﬁdence interval
(dashed line) is used to establish the shelf-life (the timepoint at
which minimum potency is reached).
One very important issue is the possibility that a mean po-
tency value at a single time point may be below the minimum
potency due to assay variability alone (see the 18 month time
point in Fig. 2B). This situation has led to uncertainty for vaccine
manufacturers and regulators on how to best deﬁne vaccine
stability (i.e., the “compliance model” where vaccine expiry is
determined by the ﬁrst test result below minimum potency vs.
the “estimation model” where statistical evaluation of all data
points is used; in this case, 18 m vs. 24 m expiry dating).
Although beyond the scope of this review, numerous scientiﬁc
papers have appeared to better address these technical issues
[58,62e64] as well as country speciﬁc and ICH regulatoryof release potency for a vaccine based on the stability proﬁle and variability of the assay
thin speciﬁcation for 24 months yet out-of-speciﬁcation (OOS) result could imply a 18
ort, storage and use [199]. Adapted and reproduced from Refs. [199,60] with permission
Table 4
Summary of Vaccine Vial Monitor (VVM) categories used during the distribution of
various vaccines (Adapted from the website of World Health Organization, 2013).
Since the VVM category used for a given vaccine is based on the stability data
available for a speciﬁc vaccine, the same vaccine type could use different VVMs
based on the manufacturer and the dosage form.
VVM category Vaccine
2 OPV
7 DTP, (DTP þ HepB þ Hib), Hib, Inﬂuenza, MR, MMR, Japanese
Encephalitis, IPV
14 DTP, TT, (DTP þ Hep B), (DTP þ Hib), (DTP þ HepB þ Hib),
Japanese Encephalitis, Measles, MR, MMR, Rubella,
Meningococcal, IPV, Rotavirus, Rubella, Yellow Fever, BCG,
Cholera, DT, Hib, Hep A, Typhoid
30 DT, TT, Hep B, HPV, Meningococcal, Pneumococcal,
Rabies, TT, Hib
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tion of vaccines [65]. As an example, for a live, attenuated viral
vaccine whose potency is monitored by an imprecise viral plaque
assay, one statistical evaluation estimated there is an ~30%
chance over a 24 month stability study that the mean potency
result for one timepoint during the study (e.g., at 0, 3, 6, 9, 12, 18,
24 months) will be below the minimum potency (due to assay
variability) even though the vaccine is stable [60,61].
For a vaccine candidate in clinical trials, a vaccine stability
program can differ from an approved vaccine in commercial dis-
tribution. For example, stability programs to support early-stage
clinical trials are focused on establishing clinically effective
ranges of vaccine potency while later-stage trials must establish a
vaccine's safety and efﬁcacy at the maximum release dose and
minimum expiry dose to formally determine shelf-life and expiry
dating. As shown in Fig. 2C, and as discussed in more detail below,
these formal stability studies must not only account for losses of
vaccine potency during manufacturing and storage, but also during
shipping and handling of the vaccine immediately prior to
administration. Post-approval stability programs include an annual
stability lot to ensure consistency of manufacturing as well as
comparability studies to support process changes [58,62]. The most
crucial element of a vaccine stability program is the real-time sta-
bility determined at the actual storage temperature over the shelf-
life of the vaccine (see Fig. 2B). Real time stability data are a
requirement for regulatory approval and post-approval annual
stability programs.
Accelerated stability studies are also performed for a variety of
supportive reasons including the determination of causes of vac-
cine inactivation (e.g., effect of solution pH or excipients), to
establish the stability-indicating nature of the potency assay, and to
evaluate comparability between different vaccine lots and
manufacturing processes [64]. In principle, accelerated stability
data generated at different temperatures could be used to estimate
stability proﬁles at lower temperatures using the Arrhenius rela-
tionship; however, due to the macromolecular complexity of vac-
cines, non-Arrhenius kinetics are often observed since the vaccine
may inactivate by different mechanisms at different temperatures
[64]. By deﬁnition, the Arrhenius relationship assumes that a vac-
cine inactivates by the same physicochemical mechanism across
the temperature range being evaluated. For example, aggregation
of viral particles is a multi-molecular event (i.e., it requires two or
more viral particles to interact) while a conformational change,
resulting in loss of protein structure or integrity of a lipid bilayer, is
an inactivation event within individual viral particles. If one
mechanism dominates at high temperature and another at lower
temperatures, then Arrhenius kinetics would not be obeyed.
Nonetheless, accelerated stability data have been successfully used
to better understand vaccine stability under real time stability
conditions with certain vaccines, especially over relatively narrow
temperature ranges (e.g., 15 and 25 C accelerated stability data
may be able estimate vaccine stability proﬁles at 2e8 C via an
Arrhenius relationship while 45 and 55 C accelerated stability
data generally does not as accurately predict lower temperature
behavior). A combination of real-time stability studies at the rec-
ommended storage temperature and accelerated stability studies at
higher temperatures are outlined in regulatory guidelines for
biotechnology products (e.g., ICH Q5C [66,67] to establish shelf-life
and expiry dating [68,69]).
7. Monitoring vaccine stability in the cold chain
During commercial production and distribution, vaccine insta-
bility and potency loss can potentially occur across the entire vac-
cine supply chain from the manufacturer to patient administration.Because of the temperature sensitive nature of vaccines, the supply
chain requires maintenance of either refrigerated or frozen tem-
peratures, often referred to as the “vaccine cold chain”. For
example, potency loss can occur during long-term storage, shipping
to various distribution centers, and the period immediately prior to
administration. The ﬁnal step, e.g., stability of a reconstituted
lyophilized vaccine over the course of one day, can often be the
most challenging in terms of maintaining appropriate storage and
handling conditions.
Although the vaccine cold chain is typically thought of as a way
to protect vaccines from inactivation due to exposure to elevated
temperatures, it is important to note that low temperatures can
also result in potency losses, e.g., inactivation of aluminum adju-
vanted vaccines due to freezing. For example, a recent study in the
United States found a high number of accidental exposures to
freezing temperatures for vaccine vials labeled for storage at 2e8 C
due to inappropriate shipping or interim storage at health centers
[70,71]. Unintended freezing of aluminum adjuvanted vaccines
during transportation and distribution in the vaccine cold chain has
become a concern in the developing world as well, since many
WHO prequaliﬁed vaccines are freeze sensitive [72]. A detailed
review of the scientiﬁc literature on the appearance of freezing
temperatures across the entire vaccine cold chain found that acci-
dental exposure to freezing temperatures at some point in distri-
bution chain occurs for 75e100% of vaccine shipments, including
14e35% of refrigerators and/or transport shipments [10]. Even
under well controlled storage conditions, the temperature can vary
throughout a refrigerator placing vaccine supplies at risk of freezing
during storage [73].
Ensuring the “vaccine cold-chain” is maintained from the fac-
tory to the end-user has led to an increasing awareness of critical
challenges (and opportunities) in securing and monitoring the
vaccine cold chain, both in the developed and developing world, to
ensure end-users worldwide are receiving efﬁcacious vaccines.
Over the past few decades, there have been enormous efforts to
implement the “vaccine cold chain” worldwide to ensure that
vaccine potency is maintained during transportation and reception,
storage at distribution centers, storage at health centers, and ﬁnally,
at the point of use [71,74e76]. Vaccine Vial Monitors (VVMs) are an
effective tool to reduce the risk that vaccines have been exposed to
potentially damaging heat conditions [77,78]. Similarly, freeze in-
dicators are used to monitor vaccines for exposure to freezing
temperatures. Various VVMs are available depending on the type of
vaccine and the target storage temperature requirements (Table 4).
The VVM category used for a given vaccine is based on the stability
data available for a speciﬁc vaccine. Therefore, the same vaccine
type could have a different VVM category based on the manufac-
turer and the ﬁnal presentation.
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distribution, but also as part of clinical development. For
example, during early clinical development when a new vaccine
antigen has been identiﬁed, a series of studies are performed to
ensure efﬁcacy and safety in preclinical animal models.
Frequently, very limited information is available on the stability
of the vaccine antigen, especially in the presence of conventional
and/or novel adjuvants, potentially leading to irreproducible re-
sults across different preparations of the experimental vaccine.
During early clinical trials, strict cold chain requirements and
surveillance of clinical supplies are important since due to
limited stability data. For example, the FDA has identiﬁed insta-
bility of clinical candidates as one of the major reasons for sus-
pension of clinical trials (i.e., clinical holds) with biological drugs
[79]. This loss of potency of clinical material can not only occur
due to temperature sensitive degradation events during storage,
but also result from other environmental stresses. For example,
inappropriate reconstitution and handling, excess agitation, and/
or light exposure can also cause vaccine inactivation [7]. As dis-
cussed below, these examples of causes of vaccine inactivation
can also play a key role in stability of commercial vaccines as
well.Fig. 3. Visual assessment and optical microscopy to detect freeze damage to an aluminum
reproduced from Ref. [92] with permission from The World Health Organization.Many different approaches to better control temperature ex-
cursions in the vaccine cold chain are being pursued. These include
new temperature monitoring technology to better identify thermal
excursions, improved training procedures and infrastructure to
reduce the frequency of their occurrence, better design and regu-
latory oversight of vaccine stability programs to address tempera-
ture excursions, and ﬁnally, adoption of testing procedures to
directly evaluate vaccine vials accidently exposed to high/low
temperatures. A recent review outlines currently available and
emerging tools to improve the cold chain including improved
temperature control strategies, better monitoring of temperature
excursions, and regulatory oversight of the supply chain [80]. For
example, additional stability studies to support product stability
during internal handling (ﬁlling, labeling, and distribution) and
external situations (unforeseen temperature excursions during
distribution, handling and administration) are receiving more
attention as part of regulatory ﬁlings [81e84].
Examples of additional stability data include temperature
cycling studies, multiple freeze-thaws, and shipping simulations to
help establish vaccine stability during temperature excursions that
may occur after the product leaves control of the manufacturer
[62,85,86]. Although it is difﬁcult to design stability programs toadjuvanted vaccine after a “shake test” followed by settling for 90 s [92]. Adapted and
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these types of studies can potentially lead to a stability database
that can establish allowed temperature and time limits for excur-
sions outside of recommended storage conditions [81]. For
example, these types of stability data have been generated for live,
attenuated [87] and subunit ﬂu vaccines [88] as well as a human
papillomavirus vaccine [89]. More recently, a meningococcal vac-
cine gained approval for storage and transport for up to four days
without refrigeration or the use of ice packs [90]. A thermal stability
test has been performed for speciﬁc lyophilized live, attenuated
vaccines to provide an indicator of consistency of production of
vaccine product in the context of lot release [9,91]. For example, in
the freeze-dried state, measles vaccines were expected to retain a
minimum potency of at least 3.0 log10 live virus particles per hu-
man dose after exposure to a temperature of 37 C for at least one
week. Additionally, the virus titer does not decrease by more than
1.0 log10 during incubation.
A “shake test” to determine if exposure to freezing conditions
has changed the physical properties of the aluminum adjuvanted
vaccine has been developed for ﬁeld use, especially in the devel-
oping world [92]. When a vaccine supply is suspected of being
exposed to freezing temperatures, selected individual vials from
that lot (test samples) are compared to a control sample from the
same vaccine (that have been intentionally frozen). The test and
control samples are shaken and then placed on a ﬂat surface and
allowed to settle by gravity. Visual observation over several mi-
nutes reveals if the aluminum adjuvant has been physically altered.
Some representative vials containing aluminum adsorbed vaccine,
including vials that have not been frozen and were intentionally
frozen, that were run in the shake test are shown in Fig. 3. The
differences in the settling behavior of the aluminum adjuvant be-
tween the vials can clearly be detected by visual observation over a
certain time period. A validation study has shown excellent
agreement between results from the simple shake test performed
by health careworkers and detailed phase microscope examination
of eight different types of WHO prequaliﬁed vaccines stored at both
5 C and exposed to freezing conditions [92] [93,94].
8. Case studies: vaccine characterization, analysis of stability
proﬁles, and examples of instability issues in the vaccine cold
chain
8.1. Inﬂuenza vaccines
Inﬂuenza is the most commonly occurring respiratory disease
caused by inﬂuenza viruses and is a leading cause of illness and
death around theworld [95,96]. Seasonal ﬂu epidemics of inﬂuenza
virus cause serious illness and millions of human infections
worldwide especially among children, elderly as well as immune
suppressed patients [97]. Inﬂuenza viruses are enveloped RNA vi-
ruses belonging to the Orthomyxoviridae family and contain eight
single-stranded RNA segments encoding 11 proteins [96,98]. The
viral particles are typically 80e120 nm in diameter and roughly
spherical in shape (see Fig. 4A). The central core of the viral parti-
cles contains the segmented RNA in association with the viral
proteins that package and protect the RNA. This core is surrounded
by the host cell membrane derived lipid envelope that contains the
two major envelope glycoproteins, hemagglutinin (HA) and neur-
aminidase (NA). The inﬂuenza viruses are divided into three types,
A, B and C, with types A and B responsible for the annual human
epidemics. Inﬂuenza A viruses are further classiﬁed into subtypes
based on the antigenic nature of hemagglutinin and neuraminidase
glycoproteins. The frequent and constant antigenic changes in the
HA and to a lesser extent in the NA proteins as a result of point
mutations and recombination events during viral replication(antigenic drift) necessitate the annual updating of the seasonal
inﬂuenza vaccines. More dramatic changes (antigenic shift) in the
HA subtype result in less frequent but more destructive inﬂuenza
pandemics [98].
Multiple approved inﬂuenza vaccines (with the same antigenic
composition) are currently available through different manufac-
turers (Table 2) [99]. Nearly all of the commercially available vac-
cines use HA and NA proteins as their primary antigens with the HA
protein being responsible for eliciting the primary neutralizing
immune response [98]. The seasonal ﬂu vaccines are usually
trivalent (or quadrivalent) and are composed of the inﬂuenza
strains (or their HA proteins) most likely to circulate in the up-
coming ﬂu season. All current ﬂu vaccines contain inﬂuenza
A(H1N1), A(H3N2), and B viral antigens. There are two antigenically
distinct strains of inﬂuenza B viruses referred to as the Victoria and
Yamagata lineages [97]. Flu vaccines are available as live-attenuated
inﬂuenza vaccines (LAIV) and trivalent inactivated vaccines (TIV), or
more recently, quadrivalent vaccines. In addition, recombinant
inﬂuenza vaccines based on recombinant HA based antigens have
been in clinical development for the past decade [100-102], and a
recombinant HA seasonal ﬂu vaccine was recently approved for
commercial use by the FDA (Flublock® produced by Protein Sci-
ences). Although the virus has traditionally been grown in chicken
eggs [97,103,104], mammalian cell lines (MDCK or Vero) have been
approved for use for inactivated vaccines inmany areas of theworld
[103,104] [105] and in the United States (Flucelvax® produced by
Novartis).
We will ﬁrst consider the formulation, analytical assays and
stability proﬁle of the live-attenuated inﬂuenza vaccines (LAIV)
vaccine as shown in Fig. 4. The live-attenuated vaccine (FluMist®,
MedImmune) is intranasally administered with a sprayer [97]. The
live virus vaccine (See Fig. 4A) is supplied as a pre-ﬁlled refriger-
ated FluMist sprayer which contains a single 0.2 mL dose with
106.5-7.5 FFU (ﬂuorescent focus units) of live attenuated inﬂuenza
virus reassortants of the viral strains. Excipients including mono-
sodium glutamate, hydrolyzed gelatin, arginine, sucrose, dibasic
potassium phosphate, and monobasic potassium phosphate are
included to optimize vaccine's stability at refrigerated tempera-
tures. The potency of LAIV is evaluated by either a TCID50 assay
(Fig. 4B) or an antibody-based ﬂuorescence focus assay (FFA; see
Fig. 4C) [87,104]. As shown in Fig. 4B, the TCID50 assay (also called
an endpoint dilution assay) quantiﬁes the amount of virus
required to produce a cytopathic effect in 50% of inoculated tissue
culture cells [106]. As shown in Fig. 4C, the FFA measures virus
infectivity per dose using immunostaining of infected MDCK cells
(ﬂuorescent focus units). The assay utilizes hemagglutinin-speciﬁc
primary antibodies followed by detection with a ﬂuorescently
labeled secondary antibody by manual counting of foci using a
ﬂuorescent microscope [87].
A representative stability proﬁle of a live virus vaccine prepa-
ration of inﬂuenza at different temperatures using the TCID50 assay
is shown in Fig. 4D. It is recommended that LAIV be stored at
refrigerated temperatures (2e8 C) before administration [87]. A
recent study [87] evaluated the immediate and long-term impact
on LAIV potency after real world temperature deviations including
freeze-thaw cycles and exposure to heat. The stability study
showed no signiﬁcant loss of potency (by viral titers measured by
the ﬂuorescence focus assay) after three freeze-thaw cycles,
warming of LAIV for 72 h at 15 C, exposure to room temperature
for 12 h or after heating to 37 C for 6 h or less. There are, however,
no published data to support the effect of long term freezing or
exposure to room or elevated temperatures for longer periods of
times on LAIV potency, and the manufacturer recommends that
LAIV be stored only at refrigerated temperatures (2e8C/35e46 F)
before administration.
Fig. 4. Structure, potency assays and stability proﬁles of live inﬂuenza vaccine. TEM micrograph of (A) live-attenuated inﬂuenza vaccine (LAIV) [200]. Potency of LAIV vaccines as
monitored by either (B) a TCID50 assay or [106] (C) a ﬂuorescence focus assay (FFA) [201]. (D) The thermal stability of LAIV vaccine as monitored by TCID50 [202]. Adapted and
reproduced from Refs. [201,202]. The image in Fig. 4C was provided courtesy of Molecular Devices, LLC.
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Fig. 5. Structure, potency assays and stability proﬁles of inactivated inﬂuenza vaccine.
(A) TEM micrograph of trivalent inactivated vaccine (TIV) [203]. (B) The potency of TIV
vaccines as monitored by SRID assay [109]. (C) The thermal stability of TIV vaccine
stability as monitored by the SRID assay [204]. Adapted and reproduced from
Refs. [109,203,204] with permission from Elsevier and Wiley.
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bility proﬁle of the inactivated trivalent inﬂuenza vaccines (TIV), or
more recently quadrivalent vaccines, as shown in Fig. 5. The inac-
tivated vaccines (whole, split or subunit; see Fig. 5A) are adminis-
tered intramuscularly (with the exception of Fluzone® Intradermal,
Sanoﬁ Pasteur). Although TIV contain varying amounts of different
viral proteins (e.g., NA, M and NP) depending on the process
methods, the hemagglutinin antigen (HA) is the main immunogen.
A minimal amount of detergent, used to disrupt the viral envelope
(in the case of split or subunit vaccines), may remain in the ﬁnal
vaccine preparation. Trace amounts of formalin or beta-
propiolactone used to inactivate the virus may also be present in
some vaccine preparations along with residual amounts of egg
proteins and antibiotics. For example, Fluvirin® (Novartis Vaccines),
a subunit (puriﬁed surface antigens) vaccine, is formulated in
phosphate buffered saline. The 5-mLmulti-dose vial formulation of
Fluvirin® contains thimerosal as a preservative. Inactivated ﬂu
vaccines licensed in the United States do not contain an adjuvant,
although adjuvants have a demonstrated capacity to enhance the
protective antibody response of some inactivated inﬂuenza vac-
cines. These include aluminum based adjuvants and oil in water
emulsions (MF59 from Novartis and ASO3 from GSK) among many
other proprietary adjuvants [107]. Several seasonal ﬂu vaccines
with adjuvants have been approved and are used in Europe [105].
The potency of inactivated inﬂuenza vaccines, as well as the
recently approved recombinant HA vaccines, is evaluated using a
single radial immunodiffusion (SRID) assay that measures HA
content per dose [100,108] as shown in Fig. 5B. The assay is based
on the diffusion of detergent solubilized vaccine samples into an
agarose matrix containing antibodies against the HA. The interac-
tion between antigen and antibody produces a precipitation ring
the size of which is directly proportional to the amount of antigen
present. The vaccine (HA) potency is measured by assessing the
diameter of the immunoprecipitin ring (Fig. 5B).
A representative stability proﬁle of an inactivated inﬂuenza
vaccine preparation at different temperatures using the SRID assay
is shown in Fig. 5C. Inactivated inﬂuenza vaccines should be stored
at refrigerated temperatures (2e8 C for up to one year) and should
not be frozen [97,103]. A stability study conducted on 27 full scale
production batches of sub-unit inﬂuenza vaccines showed elevated
storage temperatures increased the degradation rate of the hem-
agglutinin protein as measured by an SRID assay [88]. For example,
degradation at 25 C occurred 6e12 times faster than at 5 C
depending upon the inﬂuenza subunit vaccine strain. A statistical
evaluation of the stability data obtained, however, showed that
even for the most sensitive strain examined, exposure of the vac-
cine to room temperature for 2 weeks would not adversely affect
the shelf life claim of the inﬂuenza subunit vaccine after one year in
the refrigerator.
Additionally, mechanistic studies to evaluate the effect of envi-
ronmental stress conditions on the structural stability of commer-
cially available subunit inﬂuenza vaccines have shown that
exposure to freeze-thaw events, low pH, and high temperatures all
have adverse effects on the secondary and tertiary structure of the
hemagglutinin protein [96,101,109,110]. In fact, exposure to freezing
temperatures results in unfolding of HA caused by formation of ice
and concentration of solutes [87,96,109]. Another recent mecha-
nistic study demonstrated the partial loss of potency during storage
of recombinant HA at elevated temperatures, as measured by the
SRID assay, correlated with the formation of non-native disulﬁde
bonds including cysteine residues located in the C-terminal region
of the hemagglutinin protein [111].
Fig. 6. Structure, potency assay and stability of live, attenuated measles vaccine. (A)
TEM micrograph of measles virus (kindly provided by the CDC, in public domain) with
diameter of ~250 nm, (B) representative measles virus plaques on VERO cells used for
potency determination [124], and (C) Temperature sensitivity of Japanese measles
vaccine strains as measured by a viral plaque assay [205]. Four vaccine strains of
measles virus were assayed for plaques at 33, 35 and 37 C. Adapted and reproduced
from Refs. [124,205] with permission from Elsevier.
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Measles, a highly infectious respiratory disease, continues to be
a leading cause of global mortality among children [72]. The rec-
ommended age for measles vaccination varies between 6 and 15months [112,113]. Although measles is considered to be eradicable
due to the availability of efﬁcacious live attenuated viral vaccines
[114], these vaccines are unfortunately still underutilized in
developing countries [115]. Measles virus is a member of the
Morbillivirus genus of the Paramyxoviridae family [113]. The virus
is spherical, enveloped, single stranded, containing negative sense
RNA and is approximately 250 nm in diameter (Fig. 6A). The viruses
contain six structural proteins, three complexed with viral RNA to
form the nuclocapsid (P, L and N) while the other three (F, H andM)
are associated with the envelope. The two viral transmembrane
glycoproteins, the hemagglutinin (H) and the fusion protein (F) are
essential for the fusion of the viral envelope with the host cell
membrane, which leads to viral entry and subsequent infection.
Measles vaccines are one of the most unstable live, attenuated
viral vaccines and thus require an uninterrupted cold chain for
transportation and storage. Breaks in the cold chain can lead to less
effective vaccination programs [116e118]. The commercial measles
vaccines are lyophilized formulations of attenuated live viruses in
the presence of various stabilizers (e.g., Attenuvax® produced by
Merck; see Table 2) [113,115].Whilemost of themeasles vaccines are
produced in chick embryo ﬁbroblasts, some vaccines currently used
worldwide are produced in human diploid cells [112]. Attenuvax® is
available in a lyophilized format where the virus is derived from the
attenuated Edmonston strain and propagated in chick embryo cell
culture [119]. Each 0.5 mL dose, which requires reconstitution,
contains at least 1000 CCID50 (cell culture infectious doses) of
measles virus alongwith stabilizer andmedia components (sorbitol,
sodium phosphate, sucrose, sodium chloride, hydrolyzed gelatin,
human albumin, fetal bovine serum, other buffer and media in-
gredients and neomycin). The live attenuated measles vaccines are
administered subcutaneously or intramuscularly [113].
In the United States and many other developed countries,
measles vaccine is administered as a combination vaccine (measles,
mumps, rubella). In the United States, the only licensed MMR
vaccine is produced by Merck & Company (MMR-II®), although
other WHO recognized and internationally approved MMR vac-
cines are available in other countries. To maintain potency, MMR-
II® must be stored between 50 C and 2e8 C [120]. In 2005, a
quadrivalent vaccine produced was licensed in the United States
that combined measles, mumps, rubella and varicella vaccines
(MMRV, ProQuad® produced by Merck). The frozen formulation of
ProQuad is starting to be morewidely used in the United States and
has been shown to be as immunogenic and well tolerated as its
component vaccines, MMR-II® and Varivax® [121]. The use of
frozen ProQuad® is, however, limited to geographical locations
where a frozen cold-chain is available during transport and storage.
A refrigerator-stable formulation of ProQuad® has also been
recently developed to expand the utility of this vaccine and has
been shown to have similar safety and immunogenicity proﬁle to
its frozen counterpart [121]. The stabilization of varicella, both
monovalent and as a component of the quadrivalent vaccine, has
proven to be especially challenging and has required extensive
formulation development activities [7,122,123].
Two types of cell based tissue culture assays are used to monitor
the potency of live, attenuated measles vaccines. The viral plaque
assay measures “plaque forming units or pfu” formed in infected
cells (See Fig. 6B). The second commonly used potency assay,
TCID50 assay, was described in the previous case study. Both
methods typically use Vero cells [117,124] and are widely used for
measuring the potency of live virus vaccines during stability studies
(Fig. 6C). In its lyophilized form, the current measles vaccines are
generally stable for 2 years at 2e8 C and retain satisfactory po-
tency, up to 50% for at least 1 month at 22e25 C storage temper-
atures. They are generally stable to freeze-thaw stress [125], but
measles vaccines should be protected from light [120]. Measles
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reconstituted vaccines lose 50% of their potencywhen stored for 1 h
at 20e25 C and almost all potency when held at 37 C [113].
Moreover, these vaccines are also sensitive to light and colored
glass vials have been shown to minimize potency loss [126]. The
reconstituted product should be kept at 2e8 C and used the same
day due to both stability limitations as well as concerns for the
potential of microbial contamination (in absence of a preservative).
In contrast, the frozen MMRV vaccine must not only be transported
and stored frozen, but once reconstituted, should be discarded if
not used within 30 min [113].
Field evaluations of storage facilities and potency of lyophilized
measles vaccines over the last two decades have demonstrated the
importance of maintaining the cold chain during shipment and
storage [125,127e130]. Several examples of breaches in the cold
chain and subsequently its effect on measles vaccine potency are
summarized and reviewed [125]. These case studies establish that
an inefﬁcient cold chain can cause potency loss of otherwise efﬁ-
cacious measles containing vaccines.
There is considerable interest in new formulations with
improved thermal stability that can be administered by less inva-
sive routes of administration duringmass vaccination. For example,
there are multiple ongoing efforts to develop and evaluate aerosol
delivery of aqueous and dry powder forms of measles vaccines
[117,118,131]. The dry powder inhalable vaccines have been shown
to have enhanced thermostability and therefore may better main-
tain the potency of the vaccine during temperature excursions and
also permit vaccine distribution under ambient conditions during
segments of the cold chain [117,131]. The production of Measles
vaccines delivered in a dry powder format would also eliminate the
need for reconstitution. Aerosolized measles vaccines have been
evaluated for use in school aged children and were shown to be
more immunogenic than the subcutaneous route of administration
[132], although they were less efﬁcacious in young infants [133].
Novel formulations and excipients have recently been described
with the long term goal of dramatically improving the stability of
live virus vaccines and potentially allowing for the reduction in the
number of steps, or even elimination, of the vaccine cold chain
[134e136]. As one example, a recent study examined a novel
excipient, silk ﬁbroin protein (silk ﬁlms), on the accelerated sta-
bility proﬁle of a MMR vaccine during storage at elevated temper-
atures (25 C, 37 C, and 45 C). The authors found the silk ﬁlms
signiﬁcantly reduced the vaccine potency loss due to storage at
elevated temperatures [137].
8.3. Poliovirus vaccines
Poliomyelitis is a devastating paralytic disease caused by
infection with poliovirus. The virus can invade the central nervous
system and causes destruction of motor neurons that can result in
muscle weakness and acute ﬂaccid paralysis that progresses to
debilitating disease and possibly death [138]. Polioviruses belong to
the family Picornaviridae, which are 27e30 nm in diameter, non-
enveloped, and have a (þ) sense single-stranded RNA genome
7.5 kb in length (see Fig. 7A). The genome is surrounded by four
structural proteins: VP1, VP2, VP3, and VP4. There are 60 copies of
VP1 and VP3, and 58-59 copies of VP2 and VP4 [7,139]. Three
antigenic serotypes exist (Brunhilde, Lansing, and Leon), with the
blueprint of the capsid proteins remaining constant and variability
between serotypes residing in the neutralizing capsid epitopes
themselves [140].
Development of widespread vaccination practices has eradi-
cated the wild type virus in the Western Hemisphere [138]. In a
small number of areas of the developing world, however, polio-
myelitis remains a problem because it remains a challenge tovaccinate the entire population. Two different vaccines have been
developed that both confer >90% protection to vaccinated in-
dividuals, inactivated poliovirus (IPV) and attenuated live polio-
virus (OPV) [20]. Both types of vaccines (IPV and OPV) are derived
from poliovirus grown in monkey kidney cells (VERO cells) and can
either contain one serotype (monovalent) [141] or multiple sero-
types (multivalent). The inactivated poliovirus vaccine (IPV) was
developed by Jonas Salk in the 1950's and consists of poliovirus
Types 1, 2, and 3 that were grown in cell culture and subsequently
inactivated with formaldehyde [20]. Live attenuated poliovirus
(OPV) was originally produced by successive passages through
monkey tissue and was developed by many scientists including
Albert Sabin [20,142].
IPV is administered via subcutaneous or intramuscular injection
while OPV is given orally, to mimic infection with the wild type
virus. Individuals vaccinated with OPV can shed the attenuated
virus and non-vaccinated individuals can passively acquire the
attenuated strain. This is a major advantage of OPV over IPV, along
with intestinal immunity due to the oral route of administration.
IPV is currently administered in the United States due to eradication
of the disease in North America, although OPV remains the polio
vaccine of choice in polio endemic areas [143].
One example of an inactivated polio vaccine (IPOL® produced by
Sanoﬁ Pasteur) is given in four doses to children aged 2, 4, 6e18
months as well as a booster at age 4e6. IPOL® is a trivalent vaccine
in a liquid formulation that does not contain adjuvant. The vaccine
also contains 0.5% 2-phenoxyethanol, 0.02% formaldehyde (as
preservatives), and small amounts of antibiotics (<200 ng, from cell
the culture medium) per dose. Polioviruses are resistant to many
common inactivation reagents such as ethanol, ether, chloroform,
and non-ionic detergents, but can be inactivated by UV light, heat
(55 C), chlorine, and formaldehyde [139,144]. Inactivated polio-
virus is also formulated as a component of several combination
vaccines (Table 2). The IPV vaccine is stored at 2e8 C and should
not be frozen [145].
OPV (monovalent, bivalent, and trivalent) is available frommany
different manufacturers worldwide. One example, OPVERO® man-
ufactured by Sanfoi Pastuer, is a liquid formulation using human
albumin, magnesium chloride, polysorbate 80, and HEPES as sta-
bilizing formulation excipients. OPVERO® does not contain adju-
vant and is stored at 20 C, but can be stored at 2e8 C for up to 6
months. Potency of OPV drops signiﬁcantly when stored at elevated
temperatures [144]. Heat inactivation of poliovirus is a major
concern during the transport and storage of the vaccine prior to
administration. Further increasing the thermal stability of polio-
virus vaccines would have a positive effect by lessening the impacts
of temperature excursions. Indeed, as described below, thermal
stabilization of poliovirus vaccine has been the subject of consid-
erable research over the past few decades.
During stability studies, the potency of live, attenuated polio-
virus vaccines over time is monitored by viral plaque assay (a
representative plaque assay shown in Fig. 7B). Biophysical studies
have demonstrated that polioviruses can be inactivated by mod-
erate heat treatment (42e45 C) by ﬁrst unfolding the capsid
protein followed by degradation of the viral RNA [146]. Magne-
sium chloride (MgCl2) has been shown to increase the thermal
stability of OPV, and is included as a stabilizer in the vaccine [147].
In the late 1990s deuterium oxide (D2O) was identiﬁed as a sta-
bilizer of OPV [148]. Interestingly, D2O has also been shown to
stabilize other macromolecules [149] In a study by Chen et al., the
OPV stabilization by D2O and MgCl2 was examined by spectros-
copy and calorimetry. The authors showed that MgCl2 and D2O act
in concert to rigidify the conformation of the virus, although the
mechanisms of stabilization are different [150]. Biophysical studies
with another picornavirus (Hepatitis A) established that MgCl2
Fig. 7. Structure, potency assay and stability of live, attenuated polio vaccine. (A) TEMmicrograph of poliovirus virions (provided kindly by the CDC, public domain) with diameter of
~30 nm, (B) Poliovirus plaques on a HeLa cell monolayer [206], and (C) Time dependent thermal inactivation of the Sabin strain in the presence of various stabilizers [153]. Adapted
and reproduced from Refs. [206,153] with permission from Elsevier.
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capsid [151]. The perceived harmful effects of D2O in the formu-
lations resulted in the exclusion of D2O from consideration as a
new OPV thermal stable formulation [152]. Another study by
Verheyden et al., found an even greater increase in thermal sta-
bility when Pirodavir, a compound that binds the viral capsid, isincluded in the formulation [153]. These stability experiments
were conducted by stressing each OPV containing formulation at
42 C and measuring potency over time by a viral plaque assay
(See Fig. 7C).
Several studies have evaluated the OPV vaccines in the cold
chain in polio-endemic countries [128,154e156]. These studies
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and length of heat exposure of each OPV vial. A study by Samant
et al. examined the integrity of the cold chain in a rural district in
India. The authors focused on heat exposure of OPV at the last link
of the vaccine cold chain, in this case, community health centers.
They found 9% of the vials damaged by excessive heat that should
not be used (by readout of VVMs). The authors found that the use of
ice packs and the corresponding temperature of the vaccine carrier
were the most important factors leading to temperature damage of
OPV [154]. A study by Halm et al. investigated the effectiveness of
using OPV vaccine stored in the cold chain and then taken outside-
the-cold chain during an OPV vaccination campaign in a remote
area of Mali. The authors found that limited out of cold chain
storage of OPV is acceptable as long as the vaccine does not reach its
discard point (assessed by reading a VVM) [155]. A separate study
conducted in Chad drew similar conclusions [156].
8.4. Hepatitis B vaccines
Despite available vaccines, Hepatitis B virus (HBV) continues to
cause signiﬁcant disease worldwide with approximately 350
million people chronically infected [157]. HBV replicates in hepa-
tocytes and causes major inﬂammation in the liver. Infection with
HBV could lead to either acute or chronic infection, with chronic
infection often resulting in cirrhosis and/or hepatocellular carci-
noma [158]. HBV is a partially double-stranded DNA virus with a
3.2 kb genome. The virus is enclosed in a lipid envelope and is
~42 nm in diameter [159]. The HBV genome encodes three struc-
tural proteins and a DNA dependent DNA polymerase. The S-pro-
tein is the major lipid envelope protein (HBsAg) and contains 226
amino acids residues with a molecular weight of 26 kDa
[158,160,161]. Free HBsAg is found in the plasma of infected in-
dividuals in the form of non-infectious virus-like particles (VLPs).
These plasma derived VLPs are ~22 nm in diameter and were used
to vaccinate individuals prior to the introduction of the recombi-
nant HBsAg vaccines [162]. Upon puriﬁcation from plasma, HBsAg
VLPs were treated with heat and chemicals to ensure there were no
residual viral contaminants [163e165].
The antigen component of recombinant Hepatitis B vaccines is
the S-protein (HBsAg) which is typically expressed in yeast. A major
structural difference between the plasma-derived and yeast-
derived S-protein is the post-translational glycosylation pattern
[166]. The HBsAg protein spontaneously self-assembles into virus-
like particles (VLPs) during expression (Fig. 8A and B) [167]. HBsAg
VLPs must also form disulﬁde-linked oligomers during puriﬁcation
that are essential for immunogenicity and conformational stability
[168]. HBV vaccines are liquid formulations that contain 5e40 mcg
of HBsAg per ml and are adsorbed onto or co-precipitated with
aluminum adjuvants (Table 2). The two FDA approved vaccines
(RECOMBIVAX® produced by Merck, and ENGENERIX-B® produced
by GSK) have been formulated without preservatives in pre-ﬁlled
syringes and single-dose vials [169]. Various other HBV vaccines
are available worldwide and contain aluminum adjuvants. An
additional formulation (Fendrix® produced by GSK) is formulated
with MPL (a lipid A derivative) and aluminum phosphate as adju-
vants [170,171].
To verify immunogenicity and monitor stability, two different
potency assays are typically used (Fig. 8C). First, for the in vivo
potency assay, BALB/C mice are inoculated with HBsAg and the
antibody response is measured by ELISA. Alternatively, an in vitro
ELISA based assay is also commercially available that measures the
antigenicity of HBsAg surface antigen [172,173]. The composition of
the vaccine formulation can have a signiﬁcant impact on the sta-
bility of HBV vaccines throughout the cold chain as well tolerance
to temperature excursions. Although HBV vaccines are reasonablystable at elevated temperatures [174], it is often desirable to
formulate a vaccine to be as thermostable as possible [175]. Some
representative stability proﬁles of HBsAg vaccines under different
stress conditions, as monitored by the in vivo potency assays, are
shown in Fig. 8D.
The primary concern with the transport, handling, and storage
of HBV vaccines is avoidance of freezing. Freezing causes clumping
of the aluminum salt that signiﬁcantly reduces potency and alters
the conformation of the HBsAg (see Fig. 3, optical microscope pic-
tures). Scanning electron microscopy (SEM) and X-ray analysis on
several different WHO pre-qualiﬁed vaccines containing aluminum
adjuvant after subjecting them to freezing temperatures (25 C)
were compared to vaccines that were stored atþ5 C. HBV vaccines
that had been frozen showed signiﬁcant aluminum salt agglomer-
ation, rough structural features, and broken lattices that were not
observed in the vaccines that were stored at þ5 C [93]. Similar
observations using phase contrast microscopy have also been
described using other aluminum containing vaccines [92] (Fig. 3).
Another study by Chen et al. examined the freezing kinetics of the
HBV vaccine and correlated freezing with an increase in particle
size, changes in HBsAg protein tertiary structure, and changes in
surface charge (zeta potential) resulting in reduced immunoge-
nicity [176].
In practice, exposure of vaccines to freezing temperatures can
occur in all areas of the world. Numerous studies conducted over
the last decade highlight the importance of either maintaining
the cold chain or putting into place different storage or transport
practices that will not result in freezing aluminum salt containing
vaccines [177,178]. A study in Indonesia, for example, conducted
in 2001 and 2002, found inadvertent freezing of HBV vaccines
occurred in 75% of shipments. Most freezing occurred during
transport from province to district. Ice-free transport, air condi-
tioned storage in districts (opposed to storage in a refrigerator),
and room temperature storage at health care centers completely
eliminated freezing of the vaccines [178]. Thus, in this case, an
outside the cold chain (OCC) approach was feasible due to the
stability of the HBV vaccine at ambient temperatures; however,
the OCC approach is not always feasible, as a study by Ren et al.,
has demonstrated during transport to rural areas of Western
China during the winter [127] where HBV vaccines were exposed
to freezing temperatures. Although difﬁcult to decisively estab-
lish, it is attractive to postulate that the increase of cases of
Hepatitis B in ‘vaccinated’ populations is due to use of vaccine
that has been frozen prior to administration [177,179]. A study
conducted in Mongolia found a stark difference in anti-HBV
antibody titers within vaccinated 2 year olds in urban areas
(94.2%) and rural areas (70.4%) [179]. A subsequent study iden-
tiﬁed exposure of HBV vaccines to freezing temperatures during
transport from province to rural health centers [180]. Finally,
Davaalkham et al. [181] found signiﬁcant differences in the
effectiveness of the HBV vaccine when administered during the
winter months. Taken together, these studies suggest that frozen
vaccines were responsible for the differences in seroconversion
rates. These studies also point out the importance of proper
training of staff that will administer vaccines as well as the use of
freeze indicators.
Many formulation studies have recently been undertaken to
improve the stability of HBV vaccines to prevent loss of potency due
to freezing [52,54]. The study by Braun et al., found addition of
propylene glycol and other polyols protected HBV vaccines from
freeze-thaw mediated damage through several cycles. Addition of
propylene glycol depressed the thermodynamic freezing point of
the formulation, thus preventing aluminum salt agglomeration
[176]. Phosphate, histidine, and the pH of the buffer (pH 5.2), on the
other hand, protected the vaccine from heat stress [54]. Addition of
Fig. 8. Structure, potency assay and stability of an HBV vaccine. (A) AFM and (B) TEM micrograph of HBsAg VLPs produced from yeast [173]. (C) Potency is measured either by an
in vivomouse assay or an in vitro potency assay. Potency quantitation in both assays is measured by ELISA. (D) Effect of stabilizers added to an HBV vaccine formulation to maintain
potency after freezing as measured by an in vivo mouse potency assay [189]. Adapted and reproduced from Refs. [173,189] with permission from Elsevier.
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mouse immunogenicity assay (Fig. 8D).
9. Conclusions and future directions
Due to their inherent instability, vaccines require storage,
transportation and administration under controlled temperature
conditions. Thus, the vaccine cold chain must be carefully main-
tained across the entire supply chain during commercial distribu-
tion. Some vaccines are particularly sensitive to elevated
temperatures (e.g., live, attenuated viral vaccines) while other
vaccines lose potency if accidentally frozen (e.g., aluminum adju-
vanted vaccines). In this review, the causes and mechanisms of
vaccine instability were examined including the effects of exposure
to elevated temperatures and freezing on the delicate nature of the
three-dimensional structures of different types of macromolecular
antigens as well as on the physical integrity of aluminum adjuvants.
Moreover, analytical challenges to monitor vaccine potency over
time were shown to play a key role in assessing vaccine stability,
especially due to the inherent variability of commonly used bio-
assays often performed in cell-based formats or animal models. A
major public health concern is that the loss of vaccine potency
during storage and handling could lead to administration of sub-
potent vaccines. The inter-relationships between the nature of
different vaccine antigens and adjuvants, their corresponding po-
tency assays, and the determination of vaccine stability proﬁles in
the cold chain were described with case studies of important
commercially available vaccines including inﬂuenza, measles, polio,
and Hepatitis B.
Organizations such as the World Health Organization (WHO)
and PATH have developed strategies to better implement im-
provements in vaccine stability and the vaccine cold chain world-
wide [182,183]. Based on experiences with 22 collaborations to
improve stability of seven different vaccines antigens with 11
different vaccine manufacturers, PATH has summarized key “les-
sons learned” on vaccine stabilization projects including (1) inte-
grate stabilization efforts into early (clinical) development, (2)
circumstances where it makes sense to stabilize existing vaccines,
(3) freeze stabilization is possible for aluminum adjuvanted vac-
cines, (4) heat stabilization requires a customized approach and
results will be variable, (5) full beneﬁts of heat stable vaccines will
only be realized after changes are made in storage guidelines, (6)
trade-offs may be needed between heat-stability and other format
characteristics of a vaccine, and (7) vaccines with enhanced sta-
bility can beneﬁt both vaccine producers and purchasers [184].
Some additional practical hurdles to implement new vaccine sta-
bilization technologies include long and uncertain timelines for
implementation due to costs and regulatory requirements [11].
In the United States, improving vaccine stability across the cold
chain is a goal consistent with an emerging consensus over the past
decade, by several advisory groups for the US Government
(including the National Vaccine Advisory Committee, NVAC), of an
urgent need to improve vaccine development, production and
distribution capabilities. For example, a study by the NVAC exam-
ined potential weaknesses in the supply of childhood vaccines
[185] and identiﬁed one the ﬁve major contributing factors to
vaccine shortages as “… the high cost and complexity of the
development, approval and manufacturing, and distribution of
vaccines …”. An earlier study by the NVAC examining vaccine
development in the United States [186] points out, “It was clear that
the critical step-up from bench scale to pilot lots and then to large-
scale production, which depends on a small group of highly trained
individuals, is often a particularly vulnerable point in the devel-
opment process”, and how “… scale-up or changes in formulation
can result in a loss of potency or diminished efﬁcacy”. A review ofthe US vaccine system by a group of vaccine experts [187], which
highlights the major components and participating groups in the
US vaccine system, points out the key role of vaccine development
and manufacturing. These general concerns about the ability of the
vaccine community to rapidly develop, produce and distribute
vaccines were also noted during the H1N1 inﬂuenza pandemic in
2009. For example, a US Department of HSS report [188] outlines
the need to improve the ability of the United States to more rapidly
develop, produce and distribute vaccines and medical
countermeasures.
Despite the numerous vaccine stabilization challenges
described in this review, there are also many opportunities for
improvements. These range from short- to mid-term approaches as
well as longer-term goals. For example, improvements such as
better training and improved infrastructure are needed in the short
term to improve compliance within the existing vaccine cold chain.
In addition, there are opportunities to better employ current VVMs,
along with developing new VVM technologies, to better monitor
temperature excursions across each step of the vaccine cold chain.
In the mid-term, there are opportunities to reformulate currently
available vaccines to improve their stability in the vaccine cold
chain. For example, the use of certain pharmaceutical excipients
can potentially prevent freezing of aluminum adjuvanted vaccines
such as Hepatitis B during transient exposure to low temperatures
[182,189]. Longer term, by better understanding the physico-
chemical mechanisms of vaccine inactivation, mutations and
modiﬁcations could be introduced into vaccine antigens (e.g., site-
directed mutagenesis) to improve their inherent conformational
stability. In addition, improvements in vaccine formulation tech-
nologies, including new adjuvants, are needed along with new
physicochemical analysis approaches, to better preserve vaccine
potency during both clinical development and commercial use
[48,49]. For example, high throughput screening analysis of ex-
cipients for their ability to stabilize a variety of vaccine antigens by
biophysical methods has been described [190e192]. In addition,
high throughput robotics has been utilized to develop new liquid
formulations of a measles vaccine using a cell-based assay [193].
Additional trends and novel approaches towards vaccine stabili-
zation include use of novel excipients and evaluation of new drying
technologies [11]. By developing a better basic understanding of the
physicochemical mechanisms of vaccine inactivation [207], rational
strategies to better stabilize new vaccines, both by molecular
design and formulation strategies, will be possible in the long term.
Thus, a combination of longer-term research goals of improving
the immunogenicity and inherent stability of vaccines along with
shorter-term approaches to better utilize available vaccine cold
chain technology are required. This combination approach will not
only best ensure reduced wastage and improved vaccination rates
with current vaccines, but will also play a key role in the future
development of new vaccines to prevent and/or treat unmet
medical needs due to infectious diseases worldwide.Acknowledgments
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